BiotechTube
Antibody Design Laboratories

Antibody Design Laboratories

San Diego, United States· Est.
abdesignlabs.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $30M

Overview

Antibody Design Laboratories is a private, revenue-generating biotechnology service and platform company focused on the antibody discovery and engineering space. Its core business model combines the sale of research tools (vectors, libraries, helper phages) with fee-for-service work in antibody discovery, humanization, and expression. The company's key assets include its large naive and semi-synthetic antibody libraries, such as the ALTHEA Gold and OPAL VHH libraries, and its expertise in phage and yeast display technologies. ADL serves both academic and industrial clients, supporting early-stage therapeutic and diagnostic development.

AntibodiesBiologics

Technology Platform

Phage display and yeast display platforms for antibody and peptide discovery. Proprietary libraries include ALTHEA Gold (semi-synthetic human scFv), OPAL (naive VHH), and MIM (peptide) libraries. Offers associated vectors, helper phages, and mammalian expression systems.

Funding History

2
Total raised:$30M
Series A$25M
Seed$5M

Opportunities

Growing demand for antibody discovery and engineering services from virtual and emerging biotechs, coupled with increased interest in complex modalities like bispecifics and single-domain antibodies (VHHs), presents a significant market opportunity.
The company's proprietary libraries, such as the large naive OPAL VHH library, are key assets that differentiate its service offerings in a competitive landscape.

Risk Factors

Revenue is susceptible to fluctuations in client R&D budgets and biotech funding cycles.
The company faces intense competition from both large CROs and niche specialists.
Long-term risk exists from technological disruption, such as the rise of AI-driven in silico antibody design, which could potentially reduce reliance on traditional display-based discovery methods.

Competitive Landscape

ADL competes in a fragmented market with numerous players, including large, full-service contract research organizations (CROs) and smaller, specialized antibody discovery shops. Its differentiation lies in its deep expertise in phage display, ownership of specific high-diversity library IP, and a focused service model. Competitors range from companies like Absolute Antibody (reformatting), Bio-Rad's Bio-Legend (antibody services), to niche phage display specialists.

More companies in Biologics / Biosimilars →More companies in United States →